Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.67 |
| ▸ | LMNA | P02545 | 6/20 | 0.67 |
| ▸ | MITF | O75030 | 1/20 | 0.67 |
| ▸ | ALPG | P10696 | 1/20 | 0.67 |
| ▸ | RAD52 | P43351 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.64 |
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | BCHE | P06276 | 5/20 | 0.55 |
| ▸ | ACHE | P22303 | 5/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049423 | 0.84 | RAD52 (0.88) | KDM4EALDH1A1LMNAMITFALPG | |
| SCHEMBL5047155 | 0.80 | KDM4E (0.68) | KDM4EALDH1A1LMNARAD52KMT2A | |
| SCHEMBL5578267 | 0.78 | KDM4E (1.00) | KDM4EALDH1A1LMNAMITFALPG | |
| Hydrochloric Acid SCHEMBL5578125 | 0.77 | KDM4E (0.79) | KDM4EALDH1A1LMNAMITFALPG | |
| Hydrochloric Acid SCHEMBL5578128 | 0.76 | KDM4E (0.65) | KDM4EALDH1A1LMNAMITFALPG | |
| SCHEMBL5578341 | 0.75 | KDM4E (0.81) | KDM4EALDH1A1LMNAMITFALPG | |
| Hydrochloric Acid SCHEMBL5578010 | 0.75 | KDM4E (0.74) | KDM4EALDH1A1LMNAMITFALPG | |
| Hydrochloric Acid SCHEMBL5578269 | 0.75 | KDM4E (0.74) | KDM4EALDH1A1LMNAMITFALPG | |
| Hydrochloric Acid SCHEMBL5578330 | 0.74 | KDM4E (0.73) | KDM4EALDH1A1LMNAMITFALPG | |
| Hydrochloric Acid SCHEMBL5579198 | 0.73 | KDM4E (0.85) | KDM4EALDH1A1LMNAMITFALPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170354655-A1 | TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS | PHARMACYCLICS LLC | 2017-12-14 | — | — | US | claimed |
| EP-3220912-A1 | TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS | Pharmacyclics LLC (US) | 2017-09-27 | — | — | EP | claimed |
| WO-2016081460-A1 | TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS | PHARMACYCLICS LLC (US) | 2016-05-26 | — | — | WO | claimed |
| US-20220296628-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CUREVAC AG (DE) | 2022-09-22 | — | — | US | disclosed |
| EP-4013880-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CureVac AG (DE) | 2022-06-22 | — | — | EP | disclosed |
| CN-114502204-A | RNA combinations and compositions with reduced immunostimulatory properties | 库尔维科公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20170354655-A1 | TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS | PHARMACYCLICS LLC | 2017-12-14 | — | — | US | disclosed |
| EP-3220912-A1 | TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS | Pharmacyclics LLC (US) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016081460-A1 | TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS | PHARMACYCLICS LLC (US) | 2016-05-26 | — | — | WO | disclosed |
| US-7410975-B2 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410975-B2 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410975-B2 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20050119273-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119273-A1 | Small molecule toll-like receptor (TLR) antagonists | TLR3, TLR8, TLR7 | KDM4E 1460/4885ALDH1A1 4582/4885LMNA 4318/4885 |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | TLR3, TLR8, TLR7 | KDM4E 1460/4885ALDH1A1 4582/4885LMNA 4318/4885 |
| US-20170354655-A1 | TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS | BTK, TLR3, TLR9 | KDM4E 1626/4885ALDH1A1 4770/4885LMNA 2680/4885 |
| US-20220296628-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | TLR3, EIF2AK2, STING1 | KDM4E 3664/4885ALDH1A1 4395/4885LMNA 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.